Hebei Weimiao Biology Co., LTD 1
Location
  • Home
  • hydroxychloroquine sulfate cas747-36-4

Oct . 31, 2024 06:08 Back to list

hydroxychloroquine sulfate cas747-36-4



Hydroxychloroquine Sulfate An Overview of Its Uses and Importance


Hydroxychloroquine sulfate, with the chemical identifier CAS 747-36-4, is a medication primarily used in the treatment of several diseases, notably malaria, rheumatoid arthritis, and lupus erythematosus. Originally synthesized in the 1940s, hydroxychloroquine is a derivative of chloroquine and was developed to provide a more tolerable and safer alternative for patients, with a lower risk of side effects.


One of the most well-known applications of hydroxychloroquine is its use in combating malaria, a disease caused by parasites transmitted through the bite of infected mosquitoes. Hydroxychloroquine works by inhibiting the growth of the parasites in red blood cells, making it an effective prophylactic and therapeutic agent. Due to its relatively mild side effect profile compared to chloroquine, it became the preferred choice for malaria treatment in certain cases.


In addition to malaria, hydroxychloroquine has gained recognition for its efficacy in treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE). In rheumatoid arthritis, it helps reduce inflammation and alleviate symptoms, thereby improving the quality of life for patients. For lupus sufferers, hydroxychloroquine assists in managing skin rashes and joint pain, and it plays a crucial role in preventing disease flares.


hydroxychloroquine sulfate cas747-36-4

hydroxychloroquine sulfate cas747-36-4

Beyond its established uses, hydroxychloroquine entered the global spotlight during the COVID-19 pandemic. Initially suggested as a potential treatment for COVID-19, it garnered significant attention. However, subsequent clinical trials and studies produced mixed results regarding its effectiveness against the virus. Health authorities, including the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA), provided guidance that ultimately discouraged its use for COVID-19 outside of clinical trials, citing a lack of sufficient evidence to support its efficacy in this context.


The pharmacological properties of hydroxychloroquine stem from its ability to modify immune responses and its interference with viral replication. It is classified as an antimalarial and immunosuppressive agent, and it is believed to exert its therapeutic effects through various mechanisms, including the enhancement of lysosomal pH, which interferes with the processing of antigens. This action can lead to a decrease in the inflammatory response that characterizes many autoimmune disorders.


Despite its affordability and accessibility, hydroxychloroquine is not devoid of side effects. Common adverse effects include gastrointestinal disturbances, skin rashes, and headaches. More serious but rare side effects involve retinal toxicity, which mandates regular eye examinations for patients on long-term therapy.


In conclusion, hydroxychloroquine sulfate (CAS 747-36-4) remains a significant therapeutic agent in the treatment of malaria, rheumatoid arthritis, and lupus. While its role in combating COVID-19 has been met with skepticism and caution, the medication's historical and current relevance in medicine cannot be underestimated. Ongoing research continues to explore the full potential and safety of hydroxychloroquine, ensuring that it remains a vital component in the therapeutic arsenal against these diseases. As we move forward, maintaining an evidence-based approach will be essential in determining its appropriate uses in clinical practice.


Share
Next：

Latest news

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.


Hit enter to search or ESC to close
en_USEnglish
afAfrikaans sqAlbanian amAmharic arArabic hyArmenian azAzerbaijani euBasque belBelarusian bn_BDBengali bs_BABosnian bg_BGBulgarian caCatalan cebCebuano zh_CNChina zh_TWChina (Taiwan) coCorsican hrCroatian cs_CZCzech da_DKDanish nl_NLDutch eoEsperanto etEstonian fiFinnish fr_FRFrench fyFrisian gl_ESGalician ka_GEGeorgian de_DEGerman elGreek guGujarati htHaitian Creole haHausa hawHawaiian he_ILHebrew hi_INHindi hmnMiao hu_HUHungarian is_ISIcelandic igIgbo id_IDIndonesian gaIrish it_ITItalian jaJapanese jvJavanese knKannada kkKazakh kmKhmer rwRwandese ko_KRKorean ckbKurdish kyKyrgyz loLao laLatin lvLatvian lt_LTLithuanian lbLuxembourgish mk_MKMacedonian mgMalgashi ms_MYMalay ml_INMalayalam mtMaltese miMaori mrMarathi mnMongolian my_MMMyanmar ne_NPNepali nb_NONorwegian nyNorwegian orOccitan psPashto fa_IRPersian pl_PLPolish pt_PTPortuguese pa_INPunjabi ro_RORomanian ru_RURussian smSamoan gdScottish Gaelic sr_RSSerbian stSesotho snShona sdSindhi si_LKSinhala sk_SKSlovak sl_SISlovenian soSomali es_ESSpanish suSundanese swSwahili sv_SESwedish tlTagalog tgTajik ta_INTamil tt_RUTatar teTelugu thThai tr_TRTurkish tkTurkmen ukUkrainian urUrdu ug_CNUighur uz_UZUzbek viVietnamese cyWelsh xhBantu yiYiddish yoYoruba zuZulu en_USEnglish